Global Breast Cancer Therapeutics Market Article

1. GLOBAL BREAST CANCER THERAPEUTICS MARKET ANALYSIS, 2022-2030

2. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 CONTENTS? 1. Overview 03 2. Prevalence of Breast Cancer in the World 04 3. Types of Breast Cancer 08 4. Drugs Approved for Breast Cancer 12 5. Market Size and Key Findings 15 6. Regional Analysis 16 7. Market Dynamics 20 8. Competitive Landscape 21 9. Healthcare Policy and Regulatory Landscape 22 10. Reimbursement Scenario 23 11. Latest Trends and Innovations 24 12. Conclusion 25

3. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Overview The Global Breast Cancer Therapeutics Market is projected to grow from $18.2 Bn in 2022 to $48.0 Bn by 2030, registering a CAGR of 12.9% during the forecast period of 2022 - 2030. Breast cancer is the second most common cancer in women worldwide, after skin cancer. The global breast cancer therapeutics market is a rapidly growing market and is expected to continue to grow in the coming years. The market for breast cancer therapeutics is driven by a number of factors, including the increasing prevalence of breast cancer, the development of new and innovative drugs, and the growing demand for personalized medi- cine. The market is also benefiting from several initiatives and campaigns to raise awareness about breast cancer and the importance of early detection and treatment. Some of the key players in the breast cancer therapeutics market include AstraZeneca, Roche, Pfizer, Novartis, and Eli Lilly. These companies are investing heavily in research and development to develop new treatments and improve existing ones. They are also working to improve patient access to breast cancer treatments by expanding their distribution networks and working with healthcare providers to improve diagnosis and treatment. The breast cancer therapeutics market is segmented by type of therapy, including chemotherapy, targeted therapy, hormonal therapy, and others. The market is also segmented by types, distribution channels and regions. Overall, the global breast cancer therapeutics market is expected to continue to grow at a rapid pace in the coming years, driven by increasing demand for effective treatments and ongoing investment in research and development. Global Breast Cancer Therapeutics Market (in $ Bn) Matket is forecast to grow at a CAGR of 12.9% 48.0 42.6 37.7 33.4 29.8 26.2 23.2 20.5 18.2 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 03

4. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 What is the Prevalence of Breast Cancerin the World? With 1 in 8 cancer diagnoses worldwide, breast cancer is the most frequently diagnosed cancer kind. Each year, there are more than 2.3 Mn new instances of breast cancer in the world, and there were also approximately 685,000 deaths from this illness, with significant regional variances between different nations and global areas. Breast cancer is the primary or secondary cause of mortality for women from cancer in 95% of the world's nations. However, there are significant disparities in breast cancer survival between and within nations. Nearly 80% of breast and cervical cancer fatalities take place in low- and middle-income nations. The most significant risk factor is age, and the oldest females have the highest age-specific incidence rates. Less than one in five women with breast cancer is diagnosed before the age of 50 in the UK, while more than one-third of cases affect women beyond the age of 70. In contrast, more than half of breast cancer cases in women under 50 years old occur in less developed nations. These disparities in breast cancer incidence and survival are likely due to a number of factors, including access to healthcare, screening programs, and awareness of the signs and symptoms of breast cancer. In many low- and middle-income countries, women do not have regular access to healthcare, and screening programs for breast cancer are not widely available. As a result, breast cancer is often diagnosed at a later stage, when it is more difficult to treat and less likely to be cured. 04

5. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Estimated new cancer cases and deaths by sex, US, 2023 Estimated New Cases Estimated Deaths Cancer Site Both Sexes Male Female Both Sexes Male Female All sites 1,958,310 1,010,310 948,000 609,820 322,080 287,740 Breast 300,590 2800 297,790 43,700 530 43,170 Oral cavity & pharynx 54,540 39,290 15,250 11,580 8140 3440 Tongue 18,040 13,180 4860 2940 1950 990 Mouth 14,820 8680 6140 3090 1870 1220 Pharynx 20,070 16,340 3730 4140 3260 880 Other oral cavity 1610 1090 520 1410 1060 350 Digestive system 348,840 194,980 153,860 172,010 99,350 72,660 Esophagus 21,560 17,030 4530 16,120 12,920 3200 Stomach 26,500 15,930 10,570 11,130 6690 4440 Small intestine 12,070 6580 5490 2070 1170 900 Colon & rectum 153,020 81,860 71,160 52,550 28,470 24,080 Colon 106,970 54,420 52,550 0 0 0 Rectum 46,050 27,440 18,610 0 0 0 Anus, anal canal, & anorectum 9760 3180 6580 1870 860 1010 Liver & intrahepatic bile duct 41,210 27,980 13,230 29,380 19,000 10,380 Gallbladder & other biliary 12,220 5750 6470 4510 1900 2610 Pancreas 64,050 33,130 30,920 50,550 26,620 23,930 Other digestive organs 8450 3540 4910 3830 1720 2110 Respiratory system 256,290 131,150 125,140 132,330 71,170 61,160 Larynx 12,380 9900 2480 3820 3070 750 Lung & bronchus 238,340 117,550 120,790 127,070 67,160 59,910 Other respiratory organs 5570 3700 1870 1440 940 500 Bones & joints 3970 2160 1810 2140 1200 940 Soft tissue (including heart) 13,400 7400 6000 5140 2720 2420 Skin (excluding basal & squamous) 104,930 62,810 42,120 12,470 8480 3990 Melanoma of the skin 97,610 58,120 39,490 7990 5420 2570 Other nonepithelial skin 7320 4690 2630 4480 3060 1420 Genital system 414,350 299,540 114,810 69,660 35,640 34,020 05

6. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Uterine cervix 13,960 0 13,960 4310 0 4310 Uterine corpus 66,200 0 66,200 13,030 0 13,030 Ovary 19,710 0 19,710 13,270 0 13,270 Vulva 6470 0 6470 1670 0 1670 Vagina & other female genital 8470 0 8470 1740 0 1740 Prostate 288,300 288,300 0 34,700 34,700 0 Testis 9190 9190 0 470 470 0 Penis & other male genital 2050 2050 0 470 470 0 Urinary system 168,560 117,590 50,970 32,590 22,680 9910 Urinary bladder 82,290 62,420 19,870 16,710 12,160 4550 Kidney & renal pelvis 81,800 52,360 29,440 14,890 9920 4970 Ureter & other urinary organs 4470 2810 1660 990 600 390 Eye & orbit 3490 1900 1590 430 240 190 Brain & other nervous system 24,810 14,280 10,530 18,990 11,020 7970 Endocrine system 47,230 14,340 32,890 3240 1560 1680 Thyroid 43,720 12,540 31,180 2120 970 1150 Other endocrine 3510 1800 1710 1120 590 530 Lymphoma 89,380 49,730 39,650 21,080 12,320 8760 Hodgkin lymphoma 8830 4850 3980 900 540 360 Non‐Hodgkin lymphoma 80,550 44,880 35,670 20,180 11,780 8400 Myeloma 35,730 19,860 15,870 12,590 7000 5590 Leukemia 59,610 35,670 23,940 23,710 13,900 9810 Acute lymphocytic leukemia 6540 3660 2880 1390 700 690 Chronic lymphocytic leukemia 18,740 12,130 6610 4490 2830 1660 Acute myeloid leukemia 20,380 11,410 8970 11,310 6440 4870 Chronic myeloid leukemia 8930 5190 3740 1310 780 530 Other leukemia 5020 3280 1740 5210 3150 2060 Other & unspecified primary sites 32,590 16,810 15,780 48,160 26,130 22,030 06

7. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Depicts The Most Common Cancers Diagnosed in Men & Women In 2023 Estimated New Cases Prostate Lung & bronchus Colon & rectum Urinary bladder Melanoma of the skin Kidney & renal pelvis Non-Godgkin lymphoma Oral cavity & pharynx Leukemia Pancreas All sites Breast Lung & bronchus Colon & rectum Uterine corpus Melanoma of the skin Non-Hodgkin hymphoma Thyroid Pancreas Kidney & renal pelvis Leukemia All Sites 288,300 117,550 81,860 62,420 58,120 52,360 44,880 39,290 35,670 33,130 1,010,310 Males Females 297,790 120,790 71,160 66,200 39,490 35,670 31,180 30,920 29,440 23,940 948,000 31% 13% 8% 7% 4% 4% 3% 3% 3% 3% 100% 29% 12% 8% 6% 6% 5% 4% 4% 4% 3% 100% Estimated Deaths Lung & bronchus Prostate Colon & rectum Pancreas Liver & intrahepatic bile duct Leukemia Esophagus Urinary bladder Non-Hodgkin lymphoma Brain & other nervous system All sites 67,160 34,700 28,470 26,620 19,000 13,900 12,920 12,160 11,780 11,020 322,080 Males Females 21% 11% 9% 8% 6% 4% 4% 4% 4% 3% 100% Lung & bronchus Breast Colon & rectum Pancreas Ovary Uterine corpus Liver & intrahepatic bile duct Leukemia Non-Hodgkin lymphoma Brain & other nervous system All sites 59,910 43,170 24,080 23,930 13,270 13,030 10,380 9,810 8,400 7,970 287,740 21% 15% 8% 8% 5% 5% 4% 3% 3% 3% 100% Nearly half (48%) of all incident instances of cancer in males are for the prostate, lung and bronchus (hereafter lung), and colorectal cancers (CRCs), with 29% of diagnoses coming from prostate cancer alone. Breast cancer alone accounts for 31% of all cancer diagnoses in women, whereas lung cancer, CRC, and breast cancer together account for 52% of all new diagnoses. 07

8. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Types of Breast Cancer? There are several types of breast cancer, which are characterized based on the specific cells and tissues where the cancerous growth originates. The most common types of breast cancer are: Invasive Ductal Carcinoma (IDC) Ductal Carcinoma in Situ (DCIS) Invasive Lobular Carcinoma (ILC) Triple-negative Breast Cancer (TNBC) Metastatic Breast Cancer Tubular Breast Cancer Mucinous Breast Cancer Inflammatory Breast Cancer (IBC) Medullary Breast Cancer 08

9. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Ductal Carcinoma in Situ (DCIS): DCIS is a non-invasive form of breast cancer that develops in the milk ducts of the breast. It is considered a pre-can- cerous condition, as the abnormal cells are confined to the ducts and have not spread to nearby tissue. In the US now, DCIS accounts for 20% to 25% of breast cancer diagnoses. This has increased along with the intro- duction of screening mammography because a sizable portion of DCIS is initially discovered on screening mam- mography. DCIS made up fewer than 5% of newly diagnosed breast cancers during the pre-screening mammogra- phy period. Treatments available for Ductal Carcinoma in Situ (DCIS): Breast-conserving surgery (BCS) Mastectomy Hormone therapy after breast surgery ▪ ▪ ▪ Distribution of new DCIS type breast cancer cases in the US BY age group 20-34 Years 34-44 Years 45-54 Years 54-64 Years 64-74 Years 75-84 Years 85 Years & older 10% 28% 27% 21% 11% 2% 1% Invasive Ductal Carcinoma (IDC): IDC is the most common type of breast cancer, accounting for approximately 80% of all cases. It begins in the milk ducts of the breast but then invades the surrounding breast tissue. Treatment for invasive ductal carcinoma Invasive ductal carcinoma may be treated with: Surgery: Radiation Therapy: Chemotherapy: Hormonal Therapy Targeted Therapy Immunotherapy ▪ ▪ ▪ ▪ ▪ ▪ 09

10. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Estimated New Invasive Breast Cancer Cases among Women by Age, US, 2019 Age Numbers % <40 11,870 4 40-49 37,150 14 50-59 61,560 23 60-69 74,820 28 70-79 52,810 20 79< 30,390 11 Invasive Lobular Carcinoma (ILC): ILC originates in the lobules of the breast, which produce milk. It is less common than IDC, accounting for about 10-15% of all breast cancers. Treatment options may include surgery, radiation therapy, chemotherapy, and hormonal therapy. Inflammatory Breast Cancer (IBC): IBC is a rare and aggressive form of breast cancer that typically presents as a red, swollen, and warm breast. It occurs when cancer cells block the lymphatic vessels in the skin of the breast. Treatment for IBC usually involves a combination of different therapies, including Chemotherapy, Surgery, Radiation therapy, Targeted therapy, and Hormone therapy. Triple-negative Breast Cancer (TNBC): TNBC is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2/neu. This means that the cancer does not respond to hormonal therapy or targeted therapies that are effective for other types of breast cancer. Treatment options may include surgery, radiation therapy, chemotherapy, and targeted therapy. Lobular Carcinoma in Situ (LCIS): When abnormal cells are discovered in the breast lobules, it is known as lobular carcinoma in situ (LCIS). The breast tissue around the lobules is not affected by the atypical cells. Metastatic Breast Cancer: Stage 4 breast cancer sometimes refers to metastatic breast cancer. Other body parts are now affected by the malignancy. Usually, the liver, bones, brain, and lungs are included in this. 10

11. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 There are other types that are less commonly seen- Medullary Carcinoma: Medullary carcinoma accounts for 3-5% of all breast cancer types. While the tumour frequently appears on mam- mography, it is not always felt as a bump. It can occasionally resemble a spongy breast tissue alteration. Tubular Carcinoma: Tubular carcinoma cells, which account for around 2% of all breast cancer diagnoses, have a recognisable tubular form. A clump of cells that can feel more like a spongy patch of breast tissue than a lump is typically discovered by a mammography. This particular kind of breast cancer typically affects women over the age of 50 and responds favourably to hormone therapy. Mucinous Carcinoma (Colloid): A percentage of breast tumours between 1% and 2% is mucinous carcinomas. Mucus production and poorly defined cells are the major characteristics that set them apart from one another. It typically has a good prognosis as well. Paget Disease of The Breast or Nipple: A uncommon kind of cancer, breast Paget disease affects the skin of the nipple and frequently the areola, the darker circle of skin surrounding the nipple. Most persons with Paget disease that is visible on the nipple also have one or more tumours inside the same breast, which are often either invasive breast cancer or ductal carcinoma in situ (1–3). The initial signs of Paget illness are usually misdiagnosed because they are easily mistaken for more wide- spread skin disorders that affect the nipple. The prognosis for Paget disease, like all breast cancers, depends on a number of variables, such as the existence or absence of invasive malignancy and whether or not it has spread to neighbouring lymph nodes. 11

12. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 What are the treatment options for Breast Cancer? The treatment of breast cancer has made remarkable strides in recent years, offering a beacon of hope to those affected by this pervasive disease. Breast cancer treatment is not a one-size-fits-all approach but rather a finely tuned orchestra of therapies tailored to the specific type, stage, and individual characteristics of the cancer. From surgical procedures designed to remove or reshape affected breast tissue to targeted therapies aimed at disrupt- ing the molecular mechanisms of cancer growth, the landscape of breast cancer treatment is as diverse as it is dynamic. This comprehensive approach encompasses the traditional pillars of surgery, chemotherapy, and radiation therapy, as well as the latest innovations in immunotherapy and precision medicine. With a better understanding of these multifaceted treatment options, patients and healthcare providers alike can navigate the complex journey towards defeating breast cancer with increased confidence and optimism. Drugs Approved to Prevent Breast Cancer Evista (Raloxifene Hydrochloride) Raloxifene Hydrochloride Soltamox (Tamoxifen Citrate) Tamoxifen Citrate ▪ ▪ ▪ ▪ 12

13. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Drugs Approved to Treat Breast Cancer Abemaciclib Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation) Ado-Trastuzumab Emtansine Afinitor (Everolimus) Afinitor Disperz (Everolimus) Alpelisib Anastrozole Aredia (Pamidronate Disodium) Arimidex (Anastrozole) Aromasin (Exemestane) Capecitabine Cyclophosphamide Docetaxel Doxorubicin Hydrochloride Elacestrant Dihydrochloride Ellence (Epirubicin Hydrochloride) Enhertu (Fam-Trastuzumab Deruxtecan-nx- ki) Epirubicin Hydrochloride Eribulin Mesylate Everolimus Exemestane 5-FU (Fluorouracil Injection) Fam-Trastuzumab Deruxtecan-nxki Fareston (Toremifene) Faslodex (Fulvestrant) Femara (Letrozole) Fluorouracil Injection Fulvestrant Gemcitabine Hydrochloride Gemzar (Gemcitabine Hydrochloride) Goserelin Acetate Halaven (Eribulin Mesylate) Herceptin Hylecta (Trastuzumab and Hyaluronidase-oysk) Herceptin (Trastuzumab) Ibrance (Palbociclib) Infugem (Gemcitabine Hydrochloride) Ixabepilone Ixempra (Ixabepilone) Kadcyla (Ado-Trastuzumab Emtansine) Keytruda (Pembrolizumab) Kisqali (Ribociclib) Lapatinib Ditosylate Letrozole Lynparza (Olaparib) Margenza (Margetuximab-cmkb) Margetuximab-cmkb Megestrol Acetate Methotrexate Sodium Neratinib Maleate Nerlynx (Neratinib Maleate) Olaparib Orserdu (Elacestrant Dihydrochloride) Paclitaxel Paclitaxel Albumin-stabilized Nanoparticle Formulation Palbociclib Pamidronate Disodium Pembrolizumab Perjeta (Pertuzumab) Pertuzumab Pertuzumab, Trastuzumab, and Hyaluroni- dase-zzxf Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Piqray (Alpelisib) Ribociclib Sacituzumab Govitecan-hziy Soltamox (Tamoxifen Citrate) Talazoparib Tosylate Talzenna (Talazoparib Tosylate) Tamoxifen Citrate Taxotere (Docetaxel) Tecentriq (Atezolizumab) Tepadina (Thiotepa) Thiotepa Toremifene Trastuzumab Trastuzumab and Hyaluronidase-oysk Trexall (Methotrexate Sodium) Trodelvy (Sacituzumab Govitecan-hziy) Tucatinib Tukysa (Tucatinib) Tykerb (Lapatinib Ditosylate) Verzenio (Abemaciclib) Vinblastine Sulfate Xeloda (Capecitabine) Zoladex (Goserelin Acetate) ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 13

14. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Drug Combinations Used in Breast Cancer AC AC-T CAF CMF FEC TAC ▪ ▪ ▪ ▪ ▪ ▪ Below is a summary of some of the drugs commonly used to treat breast cancer: Hormone therapy: This type of therapy is used for hormone receptor-positive breast cancers and includes drugs that block the effects of estrogen on the cancer cells. Examples of hormone therapy drugs include tamox- ifen, aromatase inhibitors (such as letrozole, anastrozole, and exemestane), and fulvestrant. ▪ Chemotherapy: Chemotherapy is a systemic treatment that can be used to treat various types and stages of breast cancer. Examples of chemotherapy drugs used to treat breast cancer include taxanes (such as paclitaxel and docetaxel), anthracyclines (such as doxorubicin and epirubicin), and cyclophosphamide. ▪ Targeted therapy: Targeted therapy drugs are designed to attack specific proteins or genes in cancer cells. Examples of targeted therapy drugs used to treat breast cancer include trastuzumab, pertuzumab, lapatinib, neratinib, and everolimus. ▪ Immunotherapy: Immunotherapy drugs work by stimulating the body's immune system to recognize and attack cancer cells. For breast cancer, the immunotherapy drug atezolizumab is sometimes used in combina- tion with chemotherapy for triple-negative breast cancer that is PD-L1 positive. ▪ PARP inhibitors: PARP inhibitors are a type of targeted therapy drug that work by blocking an enzyme involved in DNA repair. These drugs are used to treat BRCA-mutated breast cancer and include olaparib, talazoparib, and rucaparib. ▪ Bisphosphonates and denosumab: These drugs are used to help prevent bone loss and reduce the risk of bone metastases in breast cancer patients. Examples of bisphosphonates include zoledronic acid and pamid- ronate, while denosumab is a monoclonal antibody. ▪ 14

15. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 How big is the market for breast cancer treatments, & what are the key trends? Market Size and Key Findings Breast Cancer Therapeutics Market Size, By Region (in $ Bn) 3.822 9.1 3.458 APAC Europe Middle East Africa Latin America North America 0.728 0.273 0.819 15 The data presented is tentative & subject to change in the final report.

16. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Regional Analysis The Global Breast Cancer Therapeutics Market is categorized into five regions based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the global breast cancer drugs market in 2022 and is expected to remain dominant during the forecast period. This growth can be attributed to the presence of well-established corporations in the area, leading to the introduction of new treatments. Other contributing factors include the high incidence of breast cancer, a rising number of R&D clinical trials for breast cancer therapies, and increasing acceptance of cutting-edge medicines. For instance, the American Cancer Society predicted that there would be about 276,480 new cases of invasive breast cancer in women in the United States in 2020. Due to the rising incidence of breast cancer and increased use of cutting-edge therapies in the region, Europe is anticipated to be the second-most prominent region throughout the projection period. For instance, female breast cancer is the most prevalent cancer diagnosed in Europe, according to figures provided by the Joint Research Center (JRC) of the European Union. In the EU-27, it was predicted that more than 355,000 women would receive a breast cancer diagnosis in 2020. The region with the biggest growth is expected to be Asia Pacific, which will benefit from rising patient populations, advanced medicine demand, and considerable increases in healthcare spending. For instance, F. Hoffmann-La Roche Ltd. announced the arrival of atezolizumab, an immunotherapy medicine, in India in April 2020 for the treat- ment of metastatic triple-negative breast cancer (TNBC). In 2019, the Middle East and Africa's and Latin America's emerging markets contributed a considerably smaller contribution. But because of the increased presence of well-known firms in the regions, rising healthcare costs, soaring patient population, and high demand for sophisticated therapies, they are predicted to rise significantly over the course of the projection year. 16

17. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Breast Cancer Therapeutics Market Size, By Countries (in $ Bn) Country 2022 CAGR 2030F US 764.4 10.9% 1748.9 China 146.3 14.4% 429.2 Canada 145.6 12.9% 384.3 Japan 113.1 13.4% 309.4 Germany 66.6 11.1% 154.6 France 50.1 11.9% 123.0 UK 47.3 10.9% 108.3 Brazil 45.5 13.9% 128.9 Italy 43.7 12.4% 111.3 Spain 35.1 11.9% 86.4 India 33.1 15.9% 107.8 Saudi Arabia 30.9 14.4% 90.8 South Korea 26.6 13.9% 75.3 Australia 21.8 14.4% 64.1 Turkey 14.6 13.4% 39.8 UAE 9.1 13.9% 25.8 Egypt 5.1 14.4% 14.9 Hong Kong 2.9 13.9% 8.3 Russia 29.7 -- -- Mexico 27.3 -- -- South Africa 11.8 -- -- Indonesia 10.9 -- -- Poland 10.6 -- -- Vietnam 9.1 -- -- Austria 7.3 -- -- Kuwait 7.3 -- -- Qatar 7.3 -- -- Sweden 6.6 -- -- Portugal 5.5 -- -- Romania 5.3 -- -- 17

18. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Netherlands 4.7 -- -- Philippines 4.0 -- -- Finland 3.8 -- -- Algeria 3.6 -- -- Malaysia 2.9 -- -- Morocco 2.4 -- -- Singapore 2.2 -- -- Nigeria 1.6 -- -- Thailand -- -- -- New Zealand -- -- -- Ireland -- -- -- Norway -- -- -- Denmark -- -- -- Belgium -- -- -- Ukraine -- -- -- Bulgaria -- -- -- Venezuela -- -- -- Senegal -- -- -- Switzerland -- -- -- Lebanon -- -- -- Kenya -- -- -- Libya -- -- -- Tanzania -- -- -- Argentina -- -- -- Ecuador -- -- -- For Country Specific Breast Cancer Therapeutics Report Click here 18

19. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Estimated age-standardized incidence rates (World) in 2020, breast, all ages ASR (World) per 100 00 ≥ 69.2 53.0-69.2 41.1-53.0 30.3-41.1 < 30.3 Not applicable No data Estimated age-standardized mortality rates (World) in 2020, breast, all ages ASR (World) per 100 00 ≥ 19.4 16.6 - 19.4 13.8 - 16.6 11.5 - 13.8 < 11.5 Not applicable No data 19

20. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Market Dynamics What are the key drivers of the Global Breast Cancer Therapeutics Market? The global breast cancer therapeutics market is driven by several factors, including: Increasing incidence of breast cancer: The incidence of breast cancer is on the rise globally, with an increasing number of women being diagnosed with the disease each year. This has resulted in a growing demand for effective treatments for breast cancer, which is driving the growth of the breast cancer therapeutics market. Development of new and innovative drugs: There has been significant investment in research and development to develop new and innovative drugs for the treatment of breast cancer. These new drugs have been shown to be more effective and less toxic than traditional chemotherapy, and they are driving the growth of the breast cancer therapeutics market. Growing demand for personalized medicine: Personalized medicine is becoming increasingly important in the treatment of breast cancer. This involves tailoring treatments to the specific genetic makeup of the patient, which can result in more effective treatments and fewer side effects. The growing demand for personalized medicine is driving the growth of the breast cancer therapeutics market. Increasing healthcare expenditure: Healthcare expenditure is increasing globally, and this is leading to increased investment in the development and distribution of breast cancer therapeutics. This is driving the growth of the breast cancer therapeutics market. Awareness and education initiatives: There are many initiatives and campaigns aimed at raising awareness about breast cancer and the importance of early detection and treatment. These initiatives are driving the demand for breast cancer therapeutics, as more women are being diagnosed and treated for the disease. What are the key restraints of the Global Breast Cancer Therapeutics Market? While the global breast cancer therapeutics market is expected to grow at a significant pace, there are also several key restraints that could potentially slow down the growth of the market, including: High cost of treatments: The cost of breast cancer treatments can be very high, which can be a significant barrier to access for many patients, particularly in low- and middle-income countries. This could limit the growth of the breast cancer therapeutics market in these regions. Stringent regulatory requirements: The development and approval of new drugs for the treatment of breast cancer is a lengthy and expensive process, with stringent regulatory requirements in place to ensure safety and efficacy. This can slow down the development and approval of new treatments, which could limit the growth of the market. Side effects of treatments: Breast cancer treatments can have significant side effects, including nausea, fatigue, hair loss, and cognitive impairment. This can limit the use of these treatments, particularly in older or more frail patients, and could impact the growth of the market. Alternative treatment options: Some patients may choose to explore alternative or complementary therapies for the treatment of breast cancer, which could limit the growth of the breast cancer therapeutics market. Lack of awareness and access: Despite growing awareness about breast cancer, there are still many regions where women have limited access to healthcare and screening services. This could limit the growth of the breast cancer therapeutics market, as patients may not be diagnosed and treated in a timely manner. 20

21. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Competitive Landscape Which are the major players in the Global Breast Cancer Therapeutics Market? The global breast cancer therapeutics market is highly competitive, with several key players competing for market share. Some of the key players in the market include: AstraZeneca is a British-Swedish multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including hormone therapies, targeted therapies, and chemotherapy drugs. Roche is a Swiss multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including targeted therapies and chemo- therapy drugs. Pfizer is an American multinational pharmaceutical company that develops and manufac- tures a range of drugs for the treatment of breast cancer, including hormone therapies and chemotherapy drugs. Novartis is a Swiss multinational pharmaceutical company that develops and manufactures a range of drugs for the treatment of breast cancer, including hormone therapies, targeted therapies, and chemotherapy drugs. Eli Lilly is an American multinational pharmaceutical company that develops and manufac- tures a range of drugs for the treatment of breast cancer, including targeted therapies and chemotherapy drugs. Other key players in the global breast cancer therapeutics market include Sanofi, Merck, Celgene Corporation, and Johnson & Johnson. These companies invest heavily in research and development to develop new treatments for breast cancer, and they also work to improve patient access to breast cancer treatments by expanding their distribution networks and working with healthcare providers to improve diagnosis and treatment. 21

22. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 How do breast cancer treatment markets, healthcare policies, & reimbursement scenarios vary around the world? Healthcare Policy and Regulatory Landscape The healthcare policy and regulatory landscape for breast cancer therapeutics varies across different regions and countries. However, there are some common themes and initiatives that are aimed at improving access to breast cancer treatment and care. In the US, the Food and Drug Administration (FDA) is responsible for the regulation of drugs and therapies for the treatment of breast cancer. The FDA has established a comprehensive regulatory framework for the develop- ment, testing, and approval of new treatments for breast cancer. The agency has also implemented various initia- tives aimed at expediting the development and approval of new drugs for serious or life-threatening diseases, including breast cancer. These initiatives are aimed at increasing patient access to new and innovative therapies. In Europe, the European Medicines Agency (EMA) is responsible for the regulation of drugs and therapies for the treatment of breast cancer. The EMA has established a comprehensive regulatory framework that is aimed at ensuring the safety and efficacy of new treatments for breast cancer. The agency has also implemented various initiatives aimed at improving patient access to new and innovative therapies. In addition to regulatory agencies, there are also various healthcare policy initiatives and organizations that are working to improve access to breast cancer treatment and care. For example, the World Health Organization (WHO) has established a global breast cancer initiative aimed at improving access to screening, diagnosis, and treatment for breast cancer. The initiative is focused on improving awareness about breast cancer, increasing access to screening and diagnosis, and improving access to quality treatment and care. Overall, the healthcare policy and regulatory landscape for breast cancer therapeutics is complex and constantly evolving. However, there is a growing focus on improving patient access to innovative and effective treatments, and on improving awareness and education about breast cancer. 22

23. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 Reimbursement Scenario Reimbursement for breast cancer therapeutics varies depending on the country and the specific treatment involved. Generally, breast cancer therapeutics reimbursement is typically provided through a combination of public and private health insurance programs. In the US, reimbursement for breast cancer therapeutics is typically provided through private health insurance plans or public insurance programs such as Medicare and Medicaid. Private health insurance plans typically cover a portion of the cost of breast cancer treatments, but patients may still be responsible for co-payments, deduct- ibles, and other out-of-pocket expenses. Medicare and Medicaid also cover a portion of the cost of breast cancer treatments, but coverage varies depending on the specific treatment and the patient's eligibility. In Europe, reimbursement for breast cancer therapeutics is typically provided through national healthcare systems. Coverage and reimbursement policies vary depending on the country, but most national healthcare systems provide coverage for breast cancer treatments. In some countries, patients may be responsible for co-payments or other out-of-pocket expenses. In other regions, such as Asia and Latin America, reimbursement for breast cancer therapeutics may be provided through a combination of public and private health insurance programs. However, access to healthcare and reim- bursement for breast cancer treatments may be limited in some regions due to factors such as cost, lack of infra- structure, and limited healthcare resources. Overall, reimbursement for breast cancer therapeutics is an important factor in patient access to care. Govern- ments, regulatory agencies, and healthcare organizations are working to improve patient access to effective and affordable breast cancer treatments, including by implementing reimbursement policies that support the use of these treatments. 23

24. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 What are the latest trends and innovations in the global breast cancer market? WHO Launches New Roadmap on Breast Cancer In February 2023, the World Health Organization (WHO) launched a new Global Breast Cancer Initiative Framework that serves as a road map for achieving the goals of 2.5 Mn lives save from breast cancer by 2040. The new Framework advises nations to put the three health promotion pillars of early detection, prompt diagnosis, and thorough management of breast cancer into practise in order to meet the targets. In order to develop resource-appropriate, country-specific health systems for the delivery of breast cancer care in low- and middle-income countries, a recently published framework makes use of tried-and-true techniques. With precise critical performance metrics, it specifies three action pillars: Advising nations to prioritise breast cancer early-detection initiatives so that at least 60% of breast cancer cases are identified and treated in the early stages Breast cancer outcomes can be improved by receiving a diagnosis within 60 days of the initial appearance. After the initial presentation, treatment should begin within three months Managing breast cancer should ensure that at least 80% of patients finish the suggested course of treatment ▪ ▪ ▪ 24

25. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 AI in Breast Cancer Artificial intelligence (AI) technology has been developed by engineers at the University of Waterloo to determine whether chemotherapy before surgery would be beneficial for people with breast cancer. Choosing the best course of action for a specific breast cancer patient is currently highly challenging, and it is critical to prevent unwanted side effects from being caused by treat- ments that are unlikely to actually benefit the patient. The open-source Cancer-Net initiative's new AI system could help unsuitable candidates avoid the harmful side effects of chemotherapy and improve surgical outcomes for those who are qualified. It is lead by Dr. Alexander Wong. Conclusion The breast cancer market has seen significant growth over the past few years, driven by rising awareness of the disease, improved screening and diagnostic technologies, and advancements in treatment options. Additionally, the increasing incidence of breast cancer and the growing aging population have also contributed to the growth of the breast cancer market. In terms of regional markets, North America and Europe are currently the largest markets for breast cancer prod- ucts and services. However, emerging markets such as Asia-Pacific and Latin America are expected to grow rapidly in the coming years due to improving healthcare infrastructure, rising disposable incomes, and increasing aware- ness of breast cancer. Due to the limited research and development in these particular fields, there are few treatment options and medi- cations available for rare kinds of breast cancer. Patients and healthcare experts who are attempting to manage and treat these forms of breast cancer may find this to be a substantial obstacle. Inflammatory breast cancer, triple-negative breast cancer, and HER2-positive breast cancer are a few uncommon types of the breast cancer. It is crucial to have access to appropriate treatments because some forms of breast cancer can be more aggressive and challenging to treat than more typical forms. Overall, the global breast cancer market is expected to continue to grow in the coming years, driven by factors such as rising incidence rates, increasing awareness and screening, and advancements in treatment options. However, the high cost of cancer treatments and the lack of access to quality healthcare in certain regions remain major challenges in the breast cancer market. 25

26. Global Breast Cancer Therapeutics Market Analysis, 2022-2030 ABOUT INSIGHTS10 Insights10 is a healthcare-focused market research firm founded with an aim of being an insights-driven company in the data-driven world and delivering actionable insights that can drive decisions and strategy-making processes for our clients. It is a market research firm that provides syndicated and customized research reports in healthcare and allied industries such as Pharmaceuticals, Diseases/Therapies, Medical Devices, Digital Health, Healthcare Services, OTC and Nutraceuticals, etc. Our qualitative, acute, and result-oriented market research reports provide a comprehensive understanding of the business scenario and the latest trends related to the life sciences market. Whether you are looking to expand into new areas, develop new products, or take advantage of new opportuni- ties we have reports to help you accelerate and improve your plans by identifying unique growth prospects. www.insights10.com References https://www.cancer.gov/about-cancer/treatment/drugs/breast https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap-on-breast-cancer#:~:text=The%20 World%20Health%20Organization%20(WHO,from%20breast%20cancer%20by%202040 https://theprint.in/science/study-artificial-intelligence-detect-effectiveness-of-breast-cancer-chemotherapy/ 1359920/ 26

27. Insights, not just research CONTACT US 821, Sun Avenue One Manekbag, Ambawadi, Amdedabad, India Author Shivam Zalke Consultant, Insights10 info@insights10.com www.insights10.com? © 2023 Insights10 | All rights reserved.